On December 10, 2024, Thomas Tu, the Chief Medical Officer of Inari Medical Inc, sold 4,000 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 304,036 shares of the company.
Inari Medical Inc (NARI, Financial) is a medical device company that focuses on developing products for patients suffering from venous diseases. The company aims to transform the treatment of venous thromboembolism and other venous disorders through innovative solutions.
Over the past year, Thomas Tu has sold a total of 24,000 shares and has not purchased any shares. The insider transaction history for Inari Medical Inc shows that there have been 0 insider buys and 32 insider sells over the same timeframe.
On the day of the recent sale, shares of Inari Medical Inc were trading at $55 each, giving the stock a market cap of $3.298 billion. The company's stock has a GF Value of $84.97, resulting in a price-to-GF-Value ratio of 0.65. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
